

D Thai

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1683500/d-thaci-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

201
papers

9,809
citations

51
h-index

95
g-index

254
ext. papers

12,391
ext. citations

4.5
avg, IF

6.04
L-index

#	Paper	IF	Citations
201	Treatment Options and Goals for Patients with Generalized Pustular Psoriasis.. <i>American Journal of Clinical Dermatology</i> , 2022 ,	7.1	5
200	Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.. <i>Dermatology and Therapy</i> , 2022 , 12, 495	4	6
199	Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes.. <i>Rheumatology and Therapy</i> , 2022 , 1	4.4	0
198	Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summary. <i>Immunotherapy</i> , 2022 , 14, 5-14	3.8	2
197	Safety of Brodalumab in Plaque Psoriasis: Integrated Pooled Data from Five Clinical Trials.. <i>Acta Dermato-Venereologica</i> , 2022 ,	2.2	3
196	Dupilumab Demonstrates Rapid and Consistent Improvement in Extent and Signs of Atopic Dermatitis Across All Anatomical Regions in Pediatric Patients 6 Years of Age and Older. <i>Dermatology and Therapy</i> , 2021 , 11, 1643-1656	4	0
195	Documentation of psoriasis in routine care - expert consensus on a German data set. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021 , 19, 1463-1475	1.2	2
194	Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis. <i>Dermatology and Therapy</i> , 2021 , 11, 2147-2157	4	0
193	High rates of therapeutic changes in patients with psoriatic arthritis receiving treatment with disease-modifying antirheumatic drugs: A cross-sectional study. <i>Modern Rheumatology</i> , 2021 , 1-9	3.3	
192	Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis. <i>New England Journal of Medicine</i> , 2021 , 384, 1101-1112	59.2	54
191	Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021 , 9, 1212-1223.e6	5.4	7
190	Association of sex and systemic therapy treatment outcomes in psoriasis: a two-country, multicentre, prospective, noninterventional registry study. <i>British Journal of Dermatology</i> , 2021 ,	4	2
189	A 12-point recommendation framework to support advancement of the multidisciplinary care of psoriatic arthritis: A call to action. <i>Joint Bone Spine</i> , 2021 , 88, 105175	2.9	3
188	Prevalence and presumptive triggers of localized bullous pemphigoid. <i>Journal of Dermatology</i> , 2021 , 48, 1257-1261	1.6	1
187	POS1042 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETKY PSO-1 STUDY. <i>Annals of the Rheumatic Diseases</i> , 2021 , 60, 701-701	2.4	8
186	Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). <i>British Journal of Dermatology</i> , 2021 , 185, 323-334	4	15
185	Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. <i>Lancet, The</i> , 2021 , 397, 2151-2168	40	55

184	Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, e709-e711	4.6	1
183	Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 1686-1691	4.6	2
182	Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2). <i>British Journal of Dermatology</i> , 2021 , 184, 652-662	4	7
181	Patients with bullous pemphigoid and comorbid psoriasis present with less blisters and lower serum levels of anti-BP180 autoantibodies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 981-987	4.6	1
180	Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52 weeks (PSO-LONG trial). <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 1269-1277	4.5	18
179	Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment. <i>British Journal of Dermatology</i> , 2021 , 184, 548-550	4	1
178	Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 476-485	4.6	35
177	Dupilumab provides favourable long-term safety and efficacy in children aged 6 to 11 years. <i>British Journal of Dermatology</i> , 2021 , 184, 857-870	4	10
176	Drug survival of secukinumab, ustekinumab, and certolizumab pegol in psoriasis: a 2-year, monocentric, retrospective study. <i>Journal of Dermatological Treatment</i> , 2021 , 1-5	2.8	3
175	Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study. <i>Journal of Dermatological Treatment</i> , 2021 , 1-9	2.8	7
174	Addressing challenges associated with long-term topical treatment and benefits of proactive management in patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35 Suppl 1, 35-41	4.6	4
173	Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2021 ,	4	2
172	Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study. <i>Journal of Dermatological Treatment</i> , 2021 , 1-8	2.8	2
171	Laboratory Safety of Dupilumab in Patients Aged 6-11 Years with Severe Atopic Dermatitis: Results from a Phase III Clinical Trial. <i>Paediatric Drugs</i> , 2021 , 23, 515-527	4.2	3
170	Quality of life and patient-perceived symptoms in patients with psoriasis undergoing proactive or reactive management with the fixed-dose combination Cal/BD foam: A post-hoc analysis of PSO-LONG. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 ,	4.6	2
169	Four-Week Daily Calcipotriene/Betamethasone Dipropionate Foam Is Highly Efficacious in Patients With Psoriasis (PSO-LONG Lead-in Phase). <i>Journal of Drugs in Dermatology</i> , 2021 , 20, 436-441	2.2	2
168	Continued treatment with secukinumab is associated with high retention or regain of response. <i>British Journal of Dermatology</i> , 2020 , 182, 67-75	4	4
167	Successful Treatment of Refractory Palmoplantar Pustular Psoriasis With Apremilast: A Case Series. <i>Frontiers in Medicine</i> , 2020 , 7, 543944	4.9	5

166	Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S). <i>Dermatology and Therapy</i> , 2020 , 10, 663-670	4	10
165	Dupilumab for treatment-refractory prurigo nodularis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020 , 18, 618-624	1.2	5
164	Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. <i>American Journal of Clinical Dermatology</i> , 2020 , 21, 567-577	7.1	34
163	Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, 1282-1293	4.5	89
162	Sex-related impairment and patient needs/benefits in anogenital psoriasis: Difficult-to-communicate topics and their impact on patient-centred care. <i>PLoS ONE</i> , 2020 , 15, e0235093-7	3.7	5
161	Long-term topical management of psoriasis: the road ahead. <i>Journal of Dermatological Treatment</i> , 2020 , 1-10	2.8	19
160	Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 2809-2820	4.6	5
159	Secukinumab-induced chronic discoid lupus erythematosus. <i>JAAD Case Reports</i> , 2020 , 6, 362-364	1.4	6
158	General practice recommendations for the topical treatment of psoriasis: a modified-Delphi approach. <i>BJGP Open</i> , 2020 , 4,	3.1	5
157	BMS-986165, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor: Evaluation of Changes in Laboratory Parameters in Response to Treatment in a Phase 2 Trial in Psoriasis Patients. <i>SKIN the Journal of Cutaneous Medicine</i> , 2020 , 4, s28	2.6	4
156	AB0759 FOUR-YEAR EFFICACY AND SAFETY OF GUSELKUMAB IN PSORIASIS PATIENTS WITH AND WITHOUT PSORIATIC ARTHRITIS: A POOLED ANALYSIS FROM VOYAGE 1 AND VOYAGE 2. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1677.1-1677	2.4	
155	AB1289-HPR PERCEPTION OF THE VALUE OF DRUGS ON DIFFERENT MANIFESTATIONS OF PSORIATIC ARTHRITIS BASED ON A MULTI-STAGE EXPERT OPINION SURVEY. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 1934.2-1935	2.4	
154	Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS). <i>British Journal of Dermatology</i> , 2020 , 183, 265-275	4	14
153	Secukinumab is effective in treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and safety from the PROSPECT study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, 310-318	4.6	13
152	Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial. <i>JAMA Dermatology</i> , 2020 , 156, 131-143	5.1	43
151	Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2020 , 145, 877-884	11.5	129
150	BMS-986165, un inhibiteur oral sélectif de la tyrosine kinase 2, réduit le PASI absolu (Psoriasis Area and Severity Index) dans une étude de phase II sur le Psoriasis. <i>Annales De Dermatologie Et De Venereologie</i> , 2020 , 147, A355-A356	0.3	
149	Tolérance d'un traitement d'entretien par une association fixe de calcipotriol 0,005% (Cal) et de dipropionate de bÉamÉhasone 0,064% (DB) sous forme de mousse chez les patients atteints de psoriasis en plaques: résultats de l'étude PSO-LONG. <i>Annales De Dermatologie Et De Venereologie</i> , 2020 , 147, A318	0.3	

148	15910 Efficacy and safety of long-term tildrakizumab for plaque psoriasis: 4-year results from reSURFACE 2. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, AB163	4.5	
147	18223 Long-term proactive management of psoriasis vulgaris with fixed-dose combination of 0.005% calcipotriene and 0.064% betamethasone dipropionate foam: Results of a phase III randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2020 , 83, AB208	4.5	
146	Disease burden and treatment needs of patients with psoriasis in sexually-sensitive and visible body areas: results from a large-scale survey in routine care. <i>European Journal of Dermatology</i> , 2020 , 30, 267-278	0.8	2
145	Disease Characteristics and the Burden of Joint and Skin Involvement Amongst People With Psoriatic Arthritis: A Population Survey. <i>Rheumatology and Therapy</i> , 2020 , 7, 617-637	4.4	8
144	Klinik für Dermatologie, Allergologie und Venerologie der Universität zu Lebeck: Interaktion von Forschung und klinischer Versorgung. <i>Aktuelle Dermatologie</i> , 2020 , 46, 11-40	0.1	
143	Spotlight on Topical Long-Term Management of Plaque Psoriasis. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2020 , 13, 495-498	2.9	3
142	Adjuvant treatment with secukinumab induced long term remission in a patient with severe bullous pemphigoid. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020 , 18, 1478-1480	1.2	0
141	International observational atopic dermatitis cohort to follow natural history and treatment course: TARGET-DERM AD study design and rationale. <i>BMJ Open</i> , 2020 , 10, e039928	3	0
140	Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. <i>British Journal of Dermatology</i> , 2020 , 182, 605-617	4	59
139	Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. <i>Journal of the American Academy of Dermatology</i> , 2020 , 82, 377-388	4.5	77
138	Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension. <i>British Journal of Dermatology</i> , 2020 , 182, 85-96	4	70
137	A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment. <i>British Journal of Dermatology</i> , 2020 , 182, 869-879	4	15
136	Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis - efficacy findings up to week 12. <i>Journal of Dermatological Treatment</i> , 2020 , 1-8	2.8	5
135	Alopecia areata development in atopic dermatitis patients treated with dupilumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, e612-e613	4.6	6
134	The contribution of joint and skin improvements to the health-related quality of life of patients with psoriatic arthritis: a post hoc analysis of two randomised controlled studies. <i>Annals of the Rheumatic Diseases</i> , 2019 , 78, 1215-1219	2.4	21
133	Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis. <i>American Journal of Clinical Dermatology</i> , 2019 , 20, 443-456	7.1	65
132	Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study. <i>British Journal of Dermatology</i> , 2019 , 181, 1177-1189	4	18
131	Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). <i>Journal of Dermatological Science</i> , 2019 , 94, 266-275	4.3	59

130	Combined culture and metagenomic analyses reveal significant shifts in the composition of the cutaneous microbiome in psoriasis. <i>British Journal of Dermatology</i> , 2019 , 181, 1254-1264	4	25
129	Efficacy of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials at weeks 12 and 28. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 1098-1106	4.6	14
128	Rapid onset of action of calcipotriol/betamethasone dipropionate cutaneous foam in psoriasis, even in patients with more severe disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 1116-1123	4.6	13
127	Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials. <i>British Journal of Dermatology</i> , 2019 , 181, 80-87	4	22
126	IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications. <i>Frontiers in Immunology</i> , 2019 , 10, 3096	8.4	46
125	Secukinumab demonstrates sustained efficacy in clearing skin and improving patient-reported outcomes in patients with moderate-to-severe psoriasis through 2 years of treatment: Results from the CLEAR study. <i>Journal of the American Academy of Dermatology</i> , 2019 , 81, 1405-1409	4.5	9
124	Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. <i>Lancet, The</i> , 2019 , 394, 576-586	4.0	121
123	Impact of Secukinumab on Endothelial Dysfunction and Other Cardiovascular Disease Parameters in Psoriasis Patients over 52 Weeks. <i>Journal of Investigative Dermatology</i> , 2019 , 139, 1054-1062	4.3	95
122	Comprehensive long-term safety of adalimumab from 18 clinical trials in adult patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2019 , 180, 76-85	4	15
121	IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. <i>Journal of Autoimmunity</i> , 2019 , 96, 104-112	15.5	39
120	Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials. <i>British Journal of Dermatology</i> , 2019 , 180, 67-75	4	24
119	Topology of psoriasis in routine care: results from high-resolution analysis of 2009 patients. <i>British Journal of Dermatology</i> , 2019 , 181, 358-365	4	11
118	Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 700-708	4.6	37
117	Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 709-717	4.6	13
116	Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI-1 and CIMPASI-2). <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, 302-314.e6	4.5	94
115	Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 1507-1514	4.6	119
114	Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 741-748	4.5	18
113	The role of the microbiome in psoriasis: moving from disease description to treatment selection?. <i>British Journal of Dermatology</i> , 2018 , 178, 1020-1027	4	35

112	Multiple switches between GP2015, an etanercept biosimilar, with originator product do not impact efficacy, safety and immunogenicity in patients with chronic plaque-type psoriasis: 30-week results from the phase 3, confirmatory EGALITY study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 420-427	4.6	57
111	Secukinumab treatment of moderate to severe plaque psoriasis in routine clinical care: real-life data of prior and concomitant use of psoriasis treatments from the PROSPECT study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 411-419	4.6	14
110	Cost-of-illness of psoriasis - results of a German cross-sectional study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 174-180	4.6	15
109	Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1). <i>Rheumatology</i> , 2018 , 57, 1777-1788	3.9	15
108	Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. <i>British Journal of Dermatology</i> , 2018 , 179, 615-622	4	39
107	Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF) <i>British Journal of Dermatology</i> , 2018 , 179, 1068-1104	4	236
106	Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials. <i>Journal of the American Association of Nurse Practitioners</i> , 2018 , 30, 529-541	1	4
105	Definition of psoriasis severity in routine clinical care: current guidelines fail to capture the complexity of long-term psoriasis management. <i>British Journal of Dermatology</i> , 2018 , 179, 1385-1391	4	15
104	Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis. <i>New England Journal of Medicine</i> , 2018 , 379, 1313-1321	59.2	171
103	Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for 56 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2). <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, 310-317.e1	4.5	110
102	Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1271-1284	4.6	16
101	Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2017 , 390, 40-49	40	73
100	Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. <i>Lancet, The</i> , 2017 , 390, 276-288	40	302
99	Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial. <i>British Journal of Dermatology</i> , 2017 , 177, 1024-1032	4	39
98	Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study. <i>British Journal of Dermatology</i> , 2017 , 177, 1033-1042	4	38
97	Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial. <i>Lancet, The</i> , 2017 , 389, 2317-2327	40	246
96	Long-Term Safety and Effectiveness of Adalimumab for Moderate to Severe Psoriasis: Results from 7-Year Interim Analysis of the ESPRIT Registry. <i>Dermatology and Therapy</i> , 2017 , 7, 365-381	4	30
95	Optimizing Anti-Inflammatory and Immunomodulatory Effects of Corticosteroid and Vitamin D Analogue Fixed-Dose Combination Therapy. <i>Dermatology and Therapy</i> , 2017 , 7, 265-279	4	21

94	Comment on "Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis". <i>Journal of Investigative Dermatology</i> , 2017 , 137, 2642-2644	4.3	2
93	The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. <i>British Journal of Dermatology</i> , 2017 , 177, 222-232	4	119
92	Apremilast, an oral phosphodiesterase 4 inhibitor, improves patient-reported outcomes in the treatment of moderate to severe psoriasis: results of two phase III randomized, controlled trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 498-506	4.6	21
91	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study. <i>Journal of the American Academy of Dermatology</i> , 2017 , 76, 60-69.e9	4.5	210
90	Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. <i>Lancet, The</i> , 2016 , 387, 40-52	4.0	360
89	Effectiveness of alitretinoin in severe chronic hand eczema: PASSION, a real-world observational study. <i>Journal of Dermatological Treatment</i> , 2016 , 27, 577-583	2.8	16
88	Does Concomitant Methotrexate with Adalimumab Influence Treatment Outcomes in Patients with Psoriatic Arthritis? Data from a Large Observational Study. <i>Journal of Rheumatology</i> , 2016 , 43, 632-9	4.1	21
87	Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: Long-term efficacy and safety results from 2 randomized phase-III studies and 1 open-label long-term extension study. <i>Journal of the American Academy of Dermatology</i> , 2016 , 74, 841-50	4.5	108
86	Patient-relevant treatment goals in psoriasis. <i>Archives of Dermatological Research</i> , 2016 , 308, 69-78	3.3	67
85	The First European Evidence-based Consensus on Extra-intestinal Manifestations in Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2016 , 10, 239-54	1.5	354
84	Successful pregnancy outcome under prolonged ustekinumab treatment in a patient with Crohn's disease and paradoxical psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016 , 30, e191-e192	4.6	32
83	THU0431 Sustained Improvements in Skin Symptoms, Physical Functioning, and Quality of Life with Secukinumab versus Ustekinumab in Patients with Moderate-To-Severe Psoriasis and Concomitant Psoriatic Arthritis: 52 Week Results from The Clear Study. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 215-221	2.4	
82	Impact on quality of life of alitretinoin in severe chronic hand eczema: FUGETTA real-world study. <i>JDDG - Journal of the German Society of Dermatology</i> , 2016 , 14, 1261-1270	1.2	4
81	The German National Program on Psoriasis Health Care 2005-2015: results and experiences. <i>Archives of Dermatological Research</i> , 2016 , 308, 389-400	3.3	27
80	Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2016 , 75, 1162-1170.e3	4.5	41
79	Anti-citrullinated protein antibodies are linked to erosive disease in an observational study of patients with psoriatic arthritis. <i>Rheumatology</i> , 2016 , 55, 1791-5	3.9	20
78	A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2016 , 175, 273-86	4	297
77	Association between skin and joint involvement in patients with psoriatic arthritis treated with adalimumab: analysis of data from a German non-interventional study. <i>Dermatology</i> , 2015 , 230, 213-21	4.4	3

76	Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, 410-9.e6	4.5	49
75	Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2015 , 73, 400-9	4.5	380
74	Importance of basic therapy in psoriasis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015 , 13, 415-8	1.2	10
73	Secukinumab in psoriasis: randomized, controlled phase 3 trial results assessing the potential to improve treatment response in partial responders (STATURE). <i>British Journal of Dermatology</i> , 2015 , 173, 777-87	4	62
72	Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. <i>British Journal of Dermatology</i> , 2015 , 173, 930-9	4	186
71	Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. <i>British Journal of Dermatology</i> , 2015 , 173, 949-51	4.1	196
70	Stellenwert der Basistherapie bei Psoriasis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2015 , 13, 415-418	1.2	4
69	Pictorial representation of illness and self measure (PRISM): an effective tool to assess the burden of psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29, 2356-62	4.6	17
68	Seborrhoeic keratosis removal in a multicentre phase I/II clinical trial using a novel topical formulation (BL-5010). <i>British Journal of Dermatology</i> , 2015 , 173, 247-9	4	6
67	Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest. <i>Archives of Dermatological Research</i> , 2015 , 307, 875-83	3.3	95
66	Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29, 353-360	4.6	58
65	Validation of Dermaphot(®) for the assessment of steroid-induced skin atrophy. <i>Archives of Dermatological Research</i> , 2014 , 306, 311	3.3	
64	Improvement in aspects of sleep with etanercept and optional adjunctive topical therapy in patients with moderate-to-severe psoriasis: results from the PRISTINE trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014 , 28, 900-6	4.6	34
63	One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis. <i>British Journal of Dermatology</i> , 2014 , 170, 435-44	4	32
62	Diagnosing and treating psoriatic arthritis: an update. <i>British Journal of Dermatology</i> , 2014 , 170, 772-86	4	23
61	Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. <i>New England Journal of Medicine</i> , 2014 , 371, 130-9	59.2	841
60	GRAPPA Fellows Symposium Adjacent to the European Academy of Dermatology and Venereology (EADV) Congress, Istanbul, 2013: a meeting report. <i>Journal of Rheumatology</i> , 2014 , 41, 1197-9	4.1	3
59	Topical long-term therapy of psoriasis with vitamin D analogues, corticosteroids and their two compound formulations: position paper on evidence and use in daily practice. <i>JDDG - Journal of the German Society of Dermatology</i> , 2014 , 12, 667-82	1.2	24

58	Validation of Dermaphot(☐) for the assessment of steroid-induced skin atrophy. <i>Archives of Dermatological Research</i> , 2013 , 305, 215-21	3.3	5
57	Recommendations for detection of individual risk for comorbidities in patients with psoriasis. <i>Archives of Dermatological Research</i> , 2013 , 305, 91-8	3.3	30
56	Vascular endothelial growth factor C-induced lymphangiogenesis decreases tumor interstitial fluid pressure and tumor. <i>Translational Oncology</i> , 2013 , 6, 398-404	4.9	13
55	Modeling pattern formation in skin diseases by a cellular automaton. <i>Journal of Investigative Dermatology</i> , 2013 , 133, 567-71	4.3	5
54	Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. <i>Journal of the American Academy of Dermatology</i> , 2013 , 69, 729-735	4.5	287
53	Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. <i>British Journal of Dermatology</i> , 2013 , 168, 402-11	4	90
52	Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013 , 27, e376-83	4.6	79
51	Efficacy and safety of fumaric acid esters in patients with psoriasis on medication for comorbid conditions - a retrospective evaluation (FACTS). <i>JDDG - Journal of the German Society of Dermatology</i> , 2013 , 11, 429-35	1.2	13
50	'Nosing Around' the human skin: what information is concealed in skin odour?. <i>Experimental Dermatology</i> , 2012 , 21, 655-9	4	25
49	Patient satisfaction with injection devices: a randomized controlled study comparing two different etanercept delivery systems in moderate to severe psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012 , 26, 448-55	4.6	16
48	Influence of psoriatic arthritis on the efficacy of adalimumab and on the treatment response of other markers of psoriasis burden: subanalysis of the BELIEVE study. <i>European Journal of Dermatology</i> , 2012 , 22, 762-9	0.8	19
47	Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. <i>British Journal of Dermatology</i> , 2012 , 168, no-no	4	184
46	Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011 , 25, 1012-20	4.6	41
45	Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2011 , 25, 1187-93	4.6	84
44	Microdialysis documents changes in the micromilieu of psoriatic plaques under continuous systemic therapy. <i>Experimental Dermatology</i> , 2011 , 20, 130-3	4	16
43	Periorale Dermatitis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2011 , 9, 422-428	1.2	6
42	Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial. <i>Archives of Dermatological Research</i> , 2011 , 303, 381-8	3.3	52
41	Subcutaneous immunotherapy with a depigmented polymerized birch pollen extract--a new therapeutic option for patients with atopic dermatitis. <i>International Archives of Allergy and Immunology</i> , 2011 , 155, 252-6	3.7	29

40	Management of psoriasis in Africa and the Middle East: a review of current opinion, practice and opportunities for improvement. <i>Journal of International Medical Research</i> , 2011 , 39, 1573-88	1.4	11
39	Twice-weekly treatment with tacrolimus 0.03% ointment in children with atopic dermatitis: clinical efficacy and economic impact over 12 months. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010 , 24, 1040-6	4.6	31
38	A phase IIIb, multicentre, randomized, double-blind, vehicle-controlled study of the efficacy and safety of adalimumab with and without calcipotriol/betamethasone topical treatment in patients with moderate to severe psoriasis: the BELIEVE study. <i>British Journal of Dermatology</i> , 2010 , 163, 402-11	4	80
37	Composite measures in psoriatic arthritis: GRAPPA 2008. <i>Journal of Rheumatology</i> , 2010 , 37, 453-61	4.1	21
36	Percutaneous absorption of pimecrolimus is not increased in patients with moderate to severe atopic dermatitis when pimecrolimus cream 1% is applied under occlusion. <i>Dermatology</i> , 2010 , 221, 342-51	4.4	4
35	Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies. <i>Clinics in Dermatology</i> , 2010 , 28, 52-6	3	62
34	Ligation of beta4 integrins activates PKB/Akt and ERK1/2 by distinct pathways-relevance of the keratin filament. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2010 , 1803, 940-50	4.9	13
33	Oligonucleotides suppress PKB/Akt and act as superinductors of apoptosis in human keratinocytes. <i>Nucleic Acids Research</i> , 2009 , 37, 3850-64	20.1	3
32	International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. <i>Arthritis and Rheumatism</i> , 2009 , 61, 1235-42		83
31	Red ear syndrome and auricular erythromelalgia: the same condition?. <i>Clinical and Experimental Dermatology</i> , 2009 , 34, e626-8	1.8	22
30	Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis--a retrospective study (FUTURE). <i>JDDG - Journal of the German Society of Dermatology</i> , 2009 , 7, 603-11	1.2	67
29	Topical methyl aminolevulinate photodynamic therapy using red light-emitting diode light for multiple actinic keratoses: a randomized study. <i>Dermatologic Surgery</i> , 2009 , 35, 586-92	1.7	63
28	Topical calcineurin inhibitors for the treatment of vulvar dermatoses. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2009 , 146, 22-9	2.4	33
27	Long-term data in the treatment of psoriasis. <i>British Journal of Dermatology</i> , 2008 , 159 Suppl 2, 18-24	4	23
26	Proactive disease management with 0.03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study. <i>British Journal of Dermatology</i> , 2008 , 159, 1348-56	4.56	131
25	Evaluation of beneficial and adverse effects of glucocorticoids on a newly developed full-thickness skin model. <i>Toxicology in Vitro</i> , 2008 , 22, 747-59	3.6	51
24	A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2008 , 59, 34-40	4.5	35
23	Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis: report on five cases. <i>Archives of Dermatological Research</i> , 2008 , 300, 101-5	3.3	24

22	Oligonucleotides suppress IL-8 in skin keratinocytes in vitro and offer anti-inflammatory properties in vivo. <i>Journal of Investigative Dermatology</i> , 2007 , 127, 846-54	4.3	20
21	Psoriasis: a possible risk factor for development of coronary artery calcification. <i>British Journal of Dermatology</i> , 2007 , 156, 271-6	4	271
20	Psoriasis patients show signs of insulin resistance. <i>British Journal of Dermatology</i> , 2007 , 157, 1249-51	4	187
19	Cutaneous leishmaniasis: clinical report of two cases and review of the recent literature. <i>JDDG - Journal of the German Society of Dermatology</i> , 2007 , 5, 770-2	1.2	9
18	Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients. <i>Dermatology</i> , 2007 , 215 Suppl 1, 3-17	4.4	24
17	Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. <i>Dermatology</i> , 2006 , 212, 238-49	4.4	47
16	Use of calcipotriene cream (Dovonex cream) following acute treatment of psoriasis vulgaris with the calcipotriene/betamethasone dipropionate two-compound product (Taclonex): a randomized, parallel-group clinical trial. <i>American Journal of Clinical Dermatology</i> , 2006 , 7, 177-84	7.1	30
15	Restoration of E-cadherin sensitizes human melanoma cells for apoptosis. <i>Melanoma Research</i> , 2006 , 16, 393-403	3.3	8
14	Treatment of scabies with 5% permethrin cream: results of a German multicenter study. <i>JDDG - Journal of the German Society of Dermatology</i> , 2006 , 4, 407-13	1.2	28
13	Successful treatment of acrodermatitis continua of Hallopeau with sequential combination of calcipotriol and tacrolimus ointments. <i>Dermatology</i> , 2005 , 211, 351-5	4.4	22
12	Improved enantioselective analysis of polyunsaturated hydroxy fatty acids in psoriatic skin scales using high-performance liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005 , 819, 323-8	3.2	24
11	Treatment of psoriasis with alefacept in patients with hepatitis C infection: a report of two cases. <i>British Journal of Dermatology</i> , 2005 , 152, 1048-50	4	21
10	Complicated mycosis fungoides mimicking facial erysipelas. <i>British Journal of Dermatology</i> , 2005 , 152, 1381-3	4	6
9	Detection of human beta defensin-1 and -2 by RT-competitive multiplex PCR. <i>Archives of Dermatological Research</i> , 2005 , 296, 539-42	3.3	1
8	Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. <i>Journal of Allergy and Clinical Immunology</i> , 2004 , 114, 1183-8	11.5	54
7	Narrowband UVB and cream psoralen-UVA combination therapy for plaque-type psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2004 , 50, 734-9	4.5	47
6	Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1% results in low systemic exposure, is well tolerated, safe, and effective. An open study. <i>Dermatology</i> , 2003 , 207, 37-42	4.4	48
5	Efficacy of dexpanthenol in skin protection against irritation: a double-blind, placebo-controlled study. <i>Contact Dermatitis</i> , 2003 , 49, 80-4	2.7	63

4	Body-weight-independent dosing of cyclosporine micro-emulsion and three times weekly maintenance regimen in severe psoriasis. A randomised study. <i>Dermatology</i> , 2002 , 205, 383-8	4-4	38
3	Calcipotriol solution for the treatment of scalp psoriasis: evaluation of efficacy, safety and acceptance in 3,396 patients. <i>Dermatology</i> , 2001 , 203, 153-6	4-4	53
2	Heavy naphthen oil exhibits antipsoriatic efficacy in vivo and antiproliferative as well as differentiation-inducing effects on keratinocytes in vitro. <i>Archives of Dermatology</i> , 2000 , 136, 678-9		2
1	Tacalcitol in combination with UVB □ in vitro effects. <i>Journal of Dermatological Treatment</i> , 1998 , 9, S31-S35.8		1